Research
Molecular
Current pharmacologic options for obesity management are largely limited in number and of modest efficacy/safety profile.
Practitioners should be aware of the limitations of existing obesity medications.
StrongSupportsmedium confidence
Current pharmacologic options for obesity management are largely limited in number and of modest efficacy/safety profile.
Why this rating
The claim is based on a comprehensive review of current pharmacologic options.
Source
Novel Noninvasive Approaches to the Treatment of Obesity: From Pharmacotherapy to Gene Therapy
Angeliki M. Angelidi et al. · Endocrine Reviews · 2021
DOI 10.1210/endrev/bnab034
reviewCited 121×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →